ExThera Medical was formed in 2007 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB at the Karolinska Institute of Stockholm. We are focused address antimicrobial resistance (AMR) and on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations with field-deployable versions for biodefense and military.
ExThera Medical Corporation is a privately held Delaware C corporation with a focus in the development and commercialization of innovative device-based clinical treatments for both drug-resistant and drug-susceptible bloodstream infections.
ExThera Medical is currently in a capital growth phase. Please contact us to learn more about our current investment programs:
Greg Dollarhyde | Director
ExThera Medical Corporation